Latest From Profusa Inc.
Results Recap: Medtronic Highlights Data To Contrast With Recent Meta-Analysis That Sparked Drug-Coated Balloon Scrutiny
This week's edition of Medtech Insight's Results Recap, the weekly roundup of major device trial-results from MedDeviceTracker, includes medical device trial results announced from Jan. 11 through Jan. 24. This week's list is dominated by results presentations from the Leipzig Interventional Course (LINC) in Leipzig, Germany, including trials of devices from Medtronic, Boston Scientific, Gore, Profusa, InspireMD, and Vessi.
Digital Health company Profusa raised more than $45m in a series C financing round. The company plans to use the proceeds to bring its tiny CE-marked injectable biosensors, used to monitor tissue oxygenation in patients with peripheral artery disease, to key opinion leaders and clinicians in Europe.
Although wearable devices are only just beginning to trend in digital health, a newer, more sophisticated technology is starting to develop. Implantable sensors designed to measure in vivo functions could become a transformative technology in a way that wearable devices cannot.
The role digital health will ultimately play in the overall health care market is still evolving, but it is becoming clearer that consumers and consumer-based products will play a role. The merging of consumer and medical was evident at CES in Las Vegas, where an increasing number of businesses are showcasing new products for the digital health market, which is expected to reach $233 billion by 2020.
- Monitoring Equipment & Devices
- Research, Analytical Equipment & Supplies
- Therapeutic Areas
- Metabolic Disorders
- Wound Healing & Tissue Repair
- North America
- Parent & Subsidiaries
- Profusa Inc.
- Senior Management
- Contact Info
Phone: (415) 655-9861
345 Allerton Avenue
San Francisco, CA 94080